BioSpace News Archive

Transparency Market Research has published a new report titled ‘Adhesive Bandages Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026.’ According to the report, the global adhesive bandages market was valued at around US$ 2800 Mn in 2017.

A cell bank refers to a facility that helps in the storage of cells of certain genome for future use in medicinal needs or in some product.

AUTO1 continued favorable safety profile and high level of clinical activity, pivotal Phase 1b/2 AUTO1-AL1 program in adult ALL initiated and enrolling patients

BeiGene, Ltd. announced that data on its BTK inhibitor zanubrutinib in relapsed/refractory marginal zone lymphoma and other B-cell malignancies and its anti-PD-1 antibody tislelizumab in R/R NK/T-cell lymphomas were presented at the 25th European Hematology Association Virtual Congress, taking place on June 11-14.

Transparency Market Research has published a new report titled, “Thalassemia Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”. According to the report, the global thalassemia treatment market was valued at US$ 842.0 Mn in 2017 and is projected to expand at a CAGR of 7.9% from 2018 to 2026.

Methicillin Resistant Staphylococcus aureus is the most prevalent multi-drug resistant bacteria and a growing threat to health.

Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, reported interim data from its ongoing Phase 2 study evaluating single agent mitapivat in non-transfusion-dependent α- and β-thalassemia.

Apellis Pharmaceuticals, Inc., a global biopharmaceutical company pioneering targeted C3 therapies, presented detailed results from the Phase 3 PEGASUS study, which in January showed superiority for pegcetacoplan over eculizumab in improving hemoglobin levels in adults with paroxysmal nocturnal hemoglobinuria.

Spleen response rates in first-line patients at 12 weeks and 24 weeks in line with previously reported data and differentiated from standard of care

Burning Rock Biotech Limited, a company focused on the application of next generation sequencing technology in the field of precision oncology, announced the pricing of its initial public offering of 13,500,000 American Depositary Shares, each representing one Class A ordinary share, at a price to the public of US$16.50 per ADS.